232 related articles for article (PubMed ID: 26148662)
1. Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa.
Geyer MB; Radhakrishnan K; Giller R; Umegaki N; Harel S; Kiuru M; Morel KD; LeBoeuf N; Kandel J; Bruckner A; Fabricatore S; Chen M; Woodley D; McGrath J; Baxter-Lowe L; Uitto J; Christiano AM; Cairo MS
J Pediatr; 2015 Sep; 167(3):765-9.e1. PubMed ID: 26148662
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.
Wagner JE; Ishida-Yamamoto A; McGrath JA; Hordinsky M; Keene DR; Woodley DT; Chen M; Riddle MJ; Osborn MJ; Lund T; Dolan M; Blazar BR; Tolar J
N Engl J Med; 2010 Aug; 363(7):629-39. PubMed ID: 20818854
[TBL] [Abstract][Full Text] [Related]
3. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.
Wong T; Gammon L; Liu L; Mellerio JE; Dopping-Hepenstal PJ; Pacy J; Elia G; Jeffery R; Leigh IM; Navsaria H; McGrath JA
J Invest Dermatol; 2008 Sep; 128(9):2179-89. PubMed ID: 18385758
[TBL] [Abstract][Full Text] [Related]
4. Mild recessive dystrophic epidermolysis bullosa associated with two compound heterozygous COL7A1 mutations.
von Bartenwerffer W; Has C; Arin MJ; Tantcheva-Poór I; Kreuter A; Kremer K; Arshah T; Hoffmann M; Eming SA; Kohlhase J; Krieg T; Bruckner-Tuderman L; Hartmann K
Eur J Dermatol; 2011; 21(2):170-2. PubMed ID: 21382783
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for recessive dystrophic epidermolysis bullosa.
Titeux M; Pendaries V; Hovnanian A
Dermatol Clin; 2010 Apr; 28(2):361-6, xii. PubMed ID: 20447504
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa.
Dang N; Murrell DF
Exp Dermatol; 2008 Jul; 17(7):553-68. PubMed ID: 18558993
[TBL] [Abstract][Full Text] [Related]
7. The inversa type of recessive dystrophic epidermolysis bullosa is caused by specific arginine and glycine substitutions in type VII collagen.
van den Akker PC; Mellerio JE; Martinez AE; Liu L; Meijer R; Dopping-Hepenstal PJ; van Essen AJ; Scheffer H; Hofstra RM; McGrath JA; Jonkman MF
J Med Genet; 2011 Mar; 48(3):160-7. PubMed ID: 21113014
[TBL] [Abstract][Full Text] [Related]
8. Dystrophic epidermolysis bullosa with one dominant and one recessive mutation of the COL7A1 gene in a child with deafness.
Weinel S; Lucky AW; Uitto J; Pfendner EG; Choo D
Pediatr Dermatol; 2008; 25(2):210-4. PubMed ID: 18429782
[TBL] [Abstract][Full Text] [Related]
9. Keratinocyte-/fibroblast-targeted rescue of Col7a1-disrupted mice and generation of an exact dystrophic epidermolysis bullosa model using a human COL7A1 mutation.
Ito K; Sawamura D; Goto M; Nakamura H; Nishie W; Sakai K; Natsuga K; Shinkuma S; Shibaki A; Uitto J; Denton CP; Nakajima O; Akiyama M; Shimizu H
Am J Pathol; 2009 Dec; 175(6):2508-17. PubMed ID: 19893033
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with recessive dystrophic epidermolysis bullosa in the Netherlands: expansion of the mutation database and unusual phenotype-genotype correlations.
van den Akker PC; van Essen AJ; Kraak MM; Meijer R; Nijenhuis M; Meijer G; Hofstra RM; Pas HH; Scheffer H; Jonkman MF
J Dermatol Sci; 2009 Oct; 56(1):9-18. PubMed ID: 19665875
[TBL] [Abstract][Full Text] [Related]
11. Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa.
Perdoni C; McGrath JA; Tolar J
Stem Cell Res Ther; 2014 Nov; 5(6):121. PubMed ID: 25376815
[TBL] [Abstract][Full Text] [Related]
12. Transplanted bone marrow-derived circulating PDGFRα+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft.
Iinuma S; Aikawa E; Tamai K; Fujita R; Kikuchi Y; Chino T; Kikuta J; McGrath JA; Uitto J; Ishii M; Iizuka H; Kaneda Y
J Immunol; 2015 Feb; 194(4):1996-2003. PubMed ID: 25601922
[TBL] [Abstract][Full Text] [Related]
13. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
[TBL] [Abstract][Full Text] [Related]
14. Response of intractable skin ulcers in recessive dystrophic epidermolysis bullosa patients to an allogeneic cultured dermal substitute.
Natsuga K; Sawamura D; Goto M; Homma E; Goto-Ohguchi Y; Aoyagi S; Akiyama M; Kuroyanagi Y; Shimizu H
Acta Derm Venereol; 2010 Mar; 90(2):165-9. PubMed ID: 20169300
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Human Placental-Derived Stem Cells in Collagen VII Knockout (Recessive Dystrophic Epidermolysis Bullosa) Animal Model.
Liao Y; Ivanova L; Sivalenka R; Plumer T; Zhu H; Zhang X; Christiano AM; McGrath JA; Gurney JP; Cairo MS
Stem Cells Transl Med; 2018 Jul; 7(7):530-542. PubMed ID: 29745997
[TBL] [Abstract][Full Text] [Related]
16. HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis Bullosa.
Nagy N; Almaani N; Tanaka A; Lai-Cheong JE; Techanukul T; Mellerio JE; McGrath JA
J Invest Dermatol; 2011 Aug; 131(8):1771-4. PubMed ID: 21471992
[No Abstract] [Full Text] [Related]
17. Efficient Gene Reframing Therapy for Recessive Dystrophic Epidermolysis Bullosa with CRISPR/Cas9.
Takashima S; Shinkuma S; Fujita Y; Nomura T; Ujiie H; Natsuga K; Iwata H; Nakamura H; Vorobyev A; Abe R; Shimizu H
J Invest Dermatol; 2019 Aug; 139(8):1711-1721.e4. PubMed ID: 30831133
[TBL] [Abstract][Full Text] [Related]
18. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT
Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566
[TBL] [Abstract][Full Text] [Related]
19. COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.
Hainzl S; Peking P; Kocher T; Murauer EM; Larcher F; Del Rio M; Duarte B; Steiner M; Klausegger A; Bauer JW; Reichelt J; Koller U
Mol Ther; 2017 Nov; 25(11):2573-2584. PubMed ID: 28800953
[TBL] [Abstract][Full Text] [Related]
20. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
